Literature DB >> 27838228

Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?

Ronald M Goldenberg1, Subodh Verma2, Bruce A Perkins3, Jeremy D Gilbert4, Bernard Zinman5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27838228     DOI： 10.1016/j.jcjd.2016.08.001

Source DB:  PubMed          Journal:  Can J Diabetes        ISSN： 1499-2671            Impact factor:   4.190


× No keyword cloud information.
  3 in total

Review 1.  Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

Authors:  Magnus F Grøndahl; Damien J Keating; Tina Vilsbøll; Filip K Knop
Journal:  Curr Diab Rep       Date:  2017-10-28       Impact factor: 4.810

Review 2.  Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.

Authors:  André J Scheen
Journal:  Nat Rev Endocrinol       Date:  2020-08-27       Impact factor: 43.330

3.  The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.

Authors:  Sofie Hædersdal; Asger Lund; Elisabeth Nielsen-Hannerup; Henrik Maagensen; Gerrit van Hall; Jens J Holst; Filip K Knop; Tina Vilsbøll
Journal:  Diabetes       Date:  2020-10-01       Impact factor: 9.337
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.